Welcome to our dedicated page for Becton, Dickinson and Co. news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Co. stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.
BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.
Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.
In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.
BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.
Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.
With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.
A groundbreaking HPV self-collection screening pilot program has launched in Texas to improve cervical cancer screening in underserved communities. The study, conducted at Su Clinica in partnership with MD Anderson Cancer Center, utilizes the BD Onclarity™ HPV Assay (NYSE: BDX), recently FDA-approved for HPV self-collection screening. The initiative, supported by a $2.5 million CPRIT grant, aims to evaluate implementation effectiveness and develop scalable best practices for nationwide application. The program specifically targets communities facing healthcare barriers, offering bilingual options and financial support for uninsured patients.
BD (NYSE: BDX), a leading global medical technology company, announced its upcoming presentation at the 7th Annual Evercore ISI HealthCONx Conference. The presentation is scheduled for Tuesday, December 3, 2024, at 10:50 am Eastern Time.
Interested parties can access the live webcast through BD's investor relations website at investors.bd.com. A replay will be made available on the same webpage after the presentation concludes.
BD (BDX) reported strong Q4 and FY2024 results with Q4 revenue reaching $5.4 billion, up 6.9% as reported. Fourth quarter GAAP and adjusted diluted EPS from continuing operations grew 173.6% and 11.4% to $1.45 and $3.81 respectively. Full-year revenue reached $20.2 billion, with organic growth of 5.0%. FY2024 cash from continuing operations increased 28.5% to $3.8 billion, while Free Cash Flow grew 47.4% to $3.1 billion. The company provided FY2025 guidance projecting organic growth of 4.0% to 4.5% and adjusted diluted EPS growth of approximately 10% at midpoint.
BD (NYSE: BDX) has announced a 9.5% increase in its quarterly dividend to $1.04 per common share, payable on December 31, 2024, to shareholders of record on December 9, 2024. This marks the company's 53rd consecutive year of dividend increases, maintaining its position in the S&P 500 Dividend Aristocrats Index. The indicated annual dividend rate for fiscal year 2025 is set at $4.16 per share. Management attributes this increase to confidence in their long-term outlook and commitment to shareholder value through their BD 2025 strategy.
BD (NYSE: BDX) has launched the new BD® Intraosseous Vascular Access System, designed for rapid delivery of fluids or medication in emergency situations where IV access is challenging. The system features unique advantages including placement capability after extension set attachment and integrated passive needle tip safety. The device offers five needle length options and includes a rechargeable battery that lasts up to 12 times longer than competitors'. Clinical studies show trained users achieve a 93-97% success rate in IO placement, with less than 1% chance of serious complications. The system is now available in the U.S. market.
BD (NYSE: BDX) has been recognized among the 100 Best Corporate Citizens of 2024 by 3BL, securing the second position in the healthcare equipment and services industry for the second consecutive year. The ranking evaluates 1,000 largest U.S. public companies based on over 200 factors across seven pillars including climate change, employee relations, environment, governance, human rights, and stakeholders and society.
Chairman, CEO and president Tom Polen emphasized that corporate sustainability is integrated into BD's business strategy and influences their healthcare-focused decision-making process.
BD (NYSE: BDX) has launched a new high-throughput, robotics-compatible reagent kit for automating single-cell discovery studies. The solution includes the BD® OMICS-One XT WTA Assay and the Hamilton® Microlab™ NGS STAR automated liquid handling platform. This collaboration aims to standardize manual processes and accelerate genetic sequencing material generation.
The automation addresses challenges in DNA library preparation, such as variability, compromised data quality, throughput, high costs, and long turnaround times. It offers increased consistency, efficiency, and reproducibility in experiments, particularly beneficial for oncology and immunology research.
The BD® OMICS-One XT Library Preparation Reagent Kits and Hamilton Microlab NGS STAR platform are now commercially available worldwide.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has announced that it will report its fiscal 2024 fourth quarter and full year financial results on Thursday, Nov. 7, 2024. A news release will be issued at approximately 6:30 a.m. ET, with related presentation materials available on the company's investor relations website.
BD management will host an audio webcast at 8 a.m. ET on the same day to discuss the financial results and provide updates on operations and strategy. The company has also announced dates for its fiscal 2025 quarterly earnings webcasts, which are scheduled for February 6, May 1, July 31, and November 6, 2025.
BD (NYSE: BDX) has reached an agreement to resolve the majority of its existing hernia litigation, including cases in Rhode Island and Ohio. The settlement amount, which is confidential, falls within the company's current product litigation reserve and will be paid over multiple years. This agreement is structured to eliminate uncertainty for all stakeholders related to the settled cases.
Key points:
- No admission of liability or wrongdoing by BD
- Settlement will not impact BD's cash flow goals or capital allocation strategy
- No incremental charge to BD's consolidated income statement
- BD will continue to defend itself in unresolved cases
BD emphasizes its commitment to patient safety and product quality, acknowledging that all implantable medical devices carry inherent risks and benefits.
BD (NYSE: BDX) announced new data highlighting the effectiveness of its artificial intelligence technology in detecting controlled substance diversion in hospital operating rooms. A study conducted at an Ochsner Health medical center, published in the American Journal of Health-System Pharmacy, showed that BD HealthSight™ Diversion Management software can identify blind spots in medication movement undetected by manual processes.
Key findings include:
- 55% increase in charting discrepancies detected
- 14% increase in incidents resolved by operating room analysts
- 10% decrease in cases requiring additional documentation
- Reduction in auditor review time from 3 business days to 50 minutes
The study emphasizes the importance of advanced analytics in combating drug diversion, a persistent issue in healthcare settings.
FAQ
What is the current stock price of Becton, Dickinson and Co. (BDX)?
What is the market cap of Becton, Dickinson and Co. (BDX)?
What does Becton, Dickinson and Company (BD) specialize in?
What are BD's main business segments?
What recent projects has BD undertaken?
How much of BD's revenue comes from international markets?
What significant acquisition has BD announced recently?
How many employees does BD have?
Where can I find more information about BD's financial performance?
What is the significance of the BD FACSDiscover™ S8 Cell Sorters?
Which regulatory body recently issued a safety communication regarding syringes?
What is BD's approach to sustainability?
